These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 35632448)

  • 21. IgG Antibody Responses and Immune Persistence of Two Doses of BBIBP-CorV Vaccine or CoronaVac Vaccine in People Living with HIV (PLWH) in Shenzhen, China.
    Zeng G; Xu L; Feng S; Tang J; Wang X; Li G; Gan Y; Zheng C; Zhao J; Yang Z
    Vaccines (Basel); 2022 May; 10(6):. PubMed ID: 35746488
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of the Sinopharm's BBIBP-CorV vaccine in preventing hospital admissions and death in infected vaccinees: Results from a retrospective study in the emirate of Abu Dhabi, United Arab Emirates (UAE).
    Ismail AlHosani F; Eduardo Stanciole A; Aden B; Timoshkin A; Najim O; Abbas Zaher W; AlSayedsaleh AlDhaheri F; Al Mazrouie S; Rizvi TA; Mustafa F
    Vaccine; 2022 Mar; 40(13):2003-2010. PubMed ID: 35193793
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2.
    Wang H; Zhang Y; Huang B; Deng W; Quan Y; Wang W; Xu W; Zhao Y; Li N; Zhang J; Liang H; Bao L; Xu Y; Ding L; Zhou W; Gao H; Liu J; Niu P; Zhao L; Zhen W; Fu H; Yu S; Zhang Z; Xu G; Li C; Lou Z; Xu M; Qin C; Wu G; Gao GF; Tan W; Yang X
    Cell; 2020 Aug; 182(3):713-721.e9. PubMed ID: 32778225
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Humoral immunity of BBIBP-CorV (Sinopharm) in kidney transplant recipients: Is it time to revise vaccination strategies.
    Nafar M; Chehrazi S; Dalili N; Firouzan A; Poorrezagholi F; Samadian F; Samavat S
    Transpl Infect Dis; 2022 Apr; 24(2):e13798. PubMed ID: 35061293
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial.
    Kaabi NA; Yang YK; Du LF; Xu K; Shao S; Liang Y; Kang Y; Su JG; Zhang J; Yang T; Hussein S; ElDein MS; Yang SS; Lei W; Gao XJ; Jiang Z; Cong X; Tan Y; Wang H; Li M; Mekki HM; Zaher W; Mahmoud S; Zhang X; Qu C; Liu DY; Zhang J; Yang M; Eltantawy I; Hou JW; Lei ZH; Xiao P; Wang ZN; Yin JL; Mao XY; Zhang J; Qu L; Zhang YT; Yang XM; Wu G; Li QM
    Nat Commun; 2022 Jun; 13(1):3654. PubMed ID: 35760812
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The incidence of COVID-19 infection following emergency use authorization of BBIBP-CORV inactivated vaccine in frontline workers in the United Arab Emirates.
    Al Kaabi N; Oulhaj A; Al Hosani FI; Al Mazrouei S; Najim O; Hussein SE; Abdalla JS; Fasihuddin MS; Hassan AA; Elghazali G; Al Rumaithi A; Al Azazi J; Weber S; Beiram R; Parekh KA; Sheek-Hussein M; Yang Y; Xiaoming Y; Quliang J; Eltantawy I; Mahmoud S; Koshy A; Xiao P; Ganesan S; Elamin W; Zaher W
    Sci Rep; 2022 Jan; 12(1):490. PubMed ID: 35017530
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of Vaccination in Preventing COVID-19: A Community Study Comparing Four Vaccines.
    Kokić Z; Kon P; Djurković-Djaković O
    Vaccines (Basel); 2023 Feb; 11(3):. PubMed ID: 36992128
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and Immunogenicity of COVID-19 BBIBP-CorV Vaccine in Children 3-12 Years Old.
    Greish K; Alawadhi A; Jaradat A; Almarabheh A; AlMadhi M; Jawad J; Alsaffar B; Alalawi E; Alsayyad A; Merza A; Alalawi B; Qayed D; Humaidan A; Al Qahtani M
    Vaccines (Basel); 2022 Apr; 10(4):. PubMed ID: 35455335
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterisation of the Antibody Response in Sinopharm (BBIBP-CorV) Recipients and COVID-19 Convalescent Sera from the Republic of Moldova.
    Ulinici M; Suljič A; Poggianella M; Milan Bonotto R; Resman Rus K; Paraschiv A; Bonetti AM; Todiras M; Corlateanu A; Groppa S; Ceban E; Petrovec M; Marcello A
    Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992221
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The BBIBP-CorV inactivated COVID-19 vaccine induces robust and persistent humoral responses to SARS-CoV-2 nucleocapsid, besides spike protein in healthy adults.
    Wang Q; Ning J; Chen Y; Li B; Shi L; He T; Zhang F; Chen X; Zhai A; Wu C
    Front Microbiol; 2022; 13():1008420. PubMed ID: 36406456
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Humoral Immune Response Induced by the BBIBP-CorV Vaccine (Sinopharm) in Healthcare Workers: A Cohort Study.
    Gómez de la Torre JC; Cáceres-DelAguila JA; Muro-Rojo C; De La Cruz-Escurra N; Copaja-Corzo C; Hueda-Zavaleta M; Arenas Siles D; Benites-Zapata VA
    Trop Med Infect Dis; 2022 Apr; 7(5):. PubMed ID: 35622693
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vaccination with the Inactivated Vaccine (Sinopharm BBIBP-CorV) Ensures Protection against SARS-CoV-2 Related Disease.
    Wang C; Chen LY; Lu QB; Cui F
    Vaccines (Basel); 2022 Jun; 10(6):. PubMed ID: 35746530
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BBIBP-CorV vaccination accelerates anti-viral antibody responses in heterologous Omicron infection: A retrospective observation study in Shanghai.
    Bao Y; He L; Miao B; Zhong Z; Lu G; Bai Y; Liang Q; Ling Y; Ji P; Su B; Zhao GP; Wu H; Zhang W; Wang Y; Chen Y; Xu J
    Vaccine; 2023 May; 41(20):3258-3265. PubMed ID: 37085449
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Performance evaluation of an automatic chemiluminescence immune platform for SARS-CoV-2 neutralizing antibody after vaccination in real world.
    Li M; Jiang R; Wang E; Xiong D; Ou T; Zhang X; Dou X
    BMC Infect Dis; 2022 Feb; 22(1):157. PubMed ID: 35168557
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neutralizing immunity against SARS-CoV-2 Omicron BA.1 by infection and vaccination.
    Duan LJ; Jiang WG; Wang ZY; Yao L; Zhu KL; Meng QC; Wang BS; Li LB; Wang GL; Ma MJ
    iScience; 2022 Sep; 25(9):104886. PubMed ID: 35966041
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of the Humoral Immune Response of a Heterologous Vaccination between BBIBP-CorV and BNT162b2 with a Temporal Separation of 7 Months, in Peruvian Healthcare Workers with and without a History of SARS-CoV-2 Infection.
    Hueda-Zavaleta M; Gómez de la Torre JC; Cáceres-Del Aguila JA; Muro-Rojo C; De La Cruz-Escurra N; Arenas Siles D; Minchón-Vizconde D; Copaja-Corzo C; Bardales-Silva F; Benites-Zapata VA; Rodriguez-Morales AJ
    Vaccines (Basel); 2022 Mar; 10(4):. PubMed ID: 35455251
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of the Safety and Immunogenicity of FAKHRAVAC and BBIBP-CorV Vaccines when Administrated as Booster Dose: A Parallel Two Arms, Randomized, Double Blind Clinical Trial.
    Ahi M; Hamidi Farahani R; Basiri P; Karimi Rahjerdi A; Sheidaei A; Gohari K; Rahimi Z; Gholami F; Moradi M; Ghafoori Naeeni F; Saffar KN; Ghasemi S; Barati B; Moradi S; Monazah A; Pouranvari F; Forooghizadeh M
    Vaccines (Basel); 2022 Oct; 10(11):. PubMed ID: 36366308
    [No Abstract]   [Full Text] [Related]  

  • 38. Anti-SARS-CoV-2 Antibody Responses 5 Months Post Complete Vaccination of Moroccan Healthcare Workers.
    Assaid N; Arich S; Charoute H; Akarid K; Ezzikouri S; Maaroufi A; Sarih M
    Vaccines (Basel); 2022 Mar; 10(3):. PubMed ID: 35335097
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of the Efficacy of BBIBP-CorV Inactivated Vaccine Combined with BNT62b2 mRNA Booster Vaccine.
    Rákóczi É; Magócs G; Kovács S; Nagy B; Szűcs G; Szekanecz Z
    Diagnostics (Basel); 2023 Feb; 13(3):. PubMed ID: 36766663
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and immunogenicity of a third-dose homologous BBIBP-CorV boosting vaccination: interim results from a prospective open-label study.
    Ai J; Zhang Y; Zhang H; Zhang Q; Fu Z; Lin K; Song J; Zhao Y; Fan M; Wang H; Zhou Y; Chen X; Qiu C; Zhang W
    Emerg Microbes Infect; 2022 Dec; 11(1):639-647. PubMed ID: 35034582
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.